Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Total Debt: 2018-2024

Historic Total Debt for Akebia Therapeutics (AKBA) over the last 7 years, with Dec 2024 value amounting to $38.7 million.

  • Akebia Therapeutics' Total Debt rose 24.21% to $47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.6 million, marking a year-over-year increase of 24.21%. This contributed to the annual value of $38.7 million for FY2024, which is 11.56% up from last year.
  • Latest data reveals that Akebia Therapeutics reported Total Debt of $38.7 million as of FY2024, which was up 11.56% from $34.7 million recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Total Debt ranged from a high of $97.5 million in FY2021 and a low of $34.7 million during FY2023.
  • In the last 3 years, Akebia Therapeutics' Total Debt had a median value of $38.7 million in 2024 and averaged $46.5 million.
  • Its Total Debt has fluctuated over the past 5 years, first increased by 27.14% in 2020, then tumbled by 47.51% in 2023.
  • Akebia Therapeutics' Total Debt (MRY) stood at $96.4 million in 2020, then increased by 1.21% to $97.5 million in 2021, then tumbled by 32.26% to $66.1 million in 2022, then tumbled by 47.51% to $34.7 million in 2023, then grew by 11.56% to $38.7 million in 2024.
  • Its Total Debt stands at $38.7 million for FY2024, versus $34.7 million for FY2023 and $66.1 million for FY2022.